BioLineRx Reports Third Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Maxim Affirms BiolineRx (BLRX) at 'Buy'; BL-8040 Should be Focus for Immune Oncology Segment
November 16, 2015 2:51 PM ESTMaxim affirms BiolineRx (Nasdaq: BLRX) with a Buy rating and $4 price target following Q3 results reported Monday morning.
The firm summarized:
Pipeline Update: BL-8040 phase II data in relapsed/refractory AML (Acute Myeloid Leukemia) showing a 38% composite response rate will be presented at ASH (December 5-8, 2015), and... MoreBioLineRx (BLRX) Tops Q3 EPS by 6c
November 16, 2015 8:34 AM ESTBioLineRx (NASDAQ: BLRX) reported Q3 EPS of ($0.02), $0.06 better than the analyst estimate of ($0.08).
For earnings history and earnings-related data on BioLineRx (BLRX) click here.
... More